Janet Addison
About
Janet Addison is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Economics and Econometrics.
According to data from OpenAlex, Janet Addison has authored 41 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 17 papers in Pediatrics, Perinatology and Child Health and 11 papers in Economics and Econometrics. Recurrent topics in Janet Addison's work include Biosimilars and Bioanalytical Methods (23 papers), Pharmaceutical studies and practices (16 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Janet Addison is often cited by papers focused on Biosimilars and Bioanalytical Methods (23 papers), Pharmaceutical studies and practices (16 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Janet Addison collaborates with scholars based in Switzerland, United Kingdom and France. Janet Addison's co-authors include D. E. Rannels, Ulrich Freudensprung, Richard A. O. Bennett, Marc Froissart, Kai‐Uwe Eckardt, Tilman B. Drüeke, Anthony E. Pegg, Daniele Marcelli, Florian Kronenberg and Jürgen Floege and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American Society of Nephrology and Annals of the Rheumatic Diseases.
In The Last Decade
Janet Addison
36 papers receiving 298 citations
Peers
Janet Addison
Daniel Eriksson Germany
Salvador Tranche Spain
Vladimir Dobronravov Russia
Richard Fuquay United States
Karin Luttropp Sweden
Valentina Ientile Italy
R Correa-Rotter Mexico
Franca M. Iorember United States
Muzaffer Çakmak Türkiye
Olimpia Diadei Italy
Citations per year, relative to Janet Addison Janet Addison (= 1×)
peers
Daniel Eriksson
Countries citing papers authored by Janet Addison
Since
Specialization
Citations
This map shows the geographic impact of Janet Addison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Addison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Addison more than expected).
Fields of papers citing papers by Janet Addison
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Janet Addison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Addison. The network helps show where Janet Addison may publish in the future.
Co-authorship network of co-authors of Janet Addison
This figure shows the co-authorship network connecting the top 25 collaborators of Janet Addison. A scholar is included among the top collaborators of Janet Addison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Addison. Janet Addison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fautrel, Bruno, Yoram Bouhnik, Carine Salliot, et al.. (2024). Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study. Drugs - Real World Outcomes. 11(4). 573–591.
2.
Young, David, Clare Harris, João Gonçalves, et al.. (2024). A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS). International Journal of Clinical Pharmacy. 46(5). 1091–1101.
3.
Ray, Kausik K., Demetris Pillas, Kamlesh Khunti, et al.. (2023). Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population. SHILAP Revista de lepidopterología. 15. 100580–100580.
4.
Fautrel, Bruno, Yoram Bouhnik, Philippe Dieudé, et al.. (2023). Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study. Rheumatology Advances in Practice. 7(2).
5.
Leng, Xiaomei, Piotr Leszczyński, Sławomir Jeka, et al.. (2023). Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. The Lancet Rheumatology. 6(1). e40–e50.
6.
Bouhnik, Yoram, Franck Carbonnel, Mathurin Fuméry, et al.. (2023). The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5. Digestive and Liver Disease. 55(12). 1658–1666.
7.
Müller‐Ladner, Ulf, Axel Dignaß, Karl Gaffney, et al.. (2023). The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease. BioDrugs. 37(6). 873–889.
8.
Fautrel, Bruno, Yoram Bouhnik, Maxime Dougados, Ulrich Freudensprung, & Janet Addison. (2021). POS0614 PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NONINTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; 12-MONTH ANALYSIS. Annals of the Rheumatic Diseases. 80. 544–544.
9.
Dignaß, Axel, Javier P. Gisbert, Ulrich Freudensprung, & Janet Addison. (2021). P469 The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease. Journal of Crohn s and Colitis. 15(Supplement_1). S459–S460.
10.
Fautrel, Bruno, et al.. (2020). THU0164 PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAIIVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; AN INTERIM ANALYSIS. Annals of the Rheumatic Diseases. 79. 297–298.
11.
Ebbers, Hans C., et al.. (2019). Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review. Rheumatology and Therapy. 6(3). 317–338.
12.
Petrov, Ivo, et al.. (2018). Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria. Folia Medica. 60(3). 389–396.
13.
Addison, Janet, Michael Suranyi, Kathleen Claes, et al.. (2016). Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. Nephrology Dialysis Transplantation. 31(12). 2073–2085.
14.
Stenvinkel, Peter, Iain Gillespie, Janet Addison, et al.. (2015). Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. Journal of the American Society of Nephrology. 27(5). 1479–1486.
15.
Schaefer, Franz, Bernd Höppe, Therese Jungraithmayr, et al.. (2015). Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study. Pediatric Nephrology. 31(3). 443–453.
16.
Donck, J, et al.. (2014). Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study. Advances in Therapy. 31(11). 1155–1168.
17.
Choi, P., et al.. (2013). Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study. Advances in Therapy. 30(11). 1007–1017.
18.
Galle, Jan, Kathleen Claes, István Kiss, et al.. (2011). An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrology Dialysis Transplantation. 27(6). 2303–2311.
19.
Rannels, D. E. & Janet Addison. (1987). Uptake of exogenous spermidine by rat lungs perfused in situ. American Journal of Physiology-Endocrinology and Metabolism. 252(1). E96–E101.
20.
Seaton, Anthony, et al.. (1986). Silicosis in barium miners.. Thorax. 41(8). 591–595.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Daniel Eriksson Breakdown of academic impact, for papers by Salvador Tranche Breakdown of academic impact, for papers by Vladimir Dobronravov Breakdown of academic impact, for papers by Richard Fuquay Breakdown of academic impact, for papers by Karin Luttropp Breakdown of academic impact, for papers by Valentina Ientile Breakdown of academic impact, for papers by R Correa-Rotter Breakdown of academic impact, for papers by Franca M. Iorember Breakdown of academic impact, for papers by Muzaffer Çakmak Breakdown of academic impact, for papers by Olimpia Diadei